Clinical Trial Finder

• Restore CFTR FunctionEnrolling

  Phase 3 study of VX-659 triple combination drug in people with CF ages 12 years and older who have two copies of the F508del mutation , protocol number VX17-659-103

  This randomized, placebo-controlled study is taking place at multiple care centers across the U.S. It will look at the effectiveness and safety of the drug VX-659 in combination with ivacaftor and tezacaftor. It is for people with CF ages 12 and older who have two copies of the F508del CFTR mutation.

  • Age:

    12 Years and Older

  • Mutation(s):

    Two Copies F508del

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    7

  • Length of Participation:

    10 weeks

• Mucociliary ClearanceEnrolling

  Cohort 3 of a study to evaluate inhaled QBW276 in adults with CF , protocol number Novartis CQBW276X2201

  This randomized, placebo-controlled study is taking place at multiple care centers across the U.S. This study will look at the safety, effectiveness, and tolerability of the inhaled drug QBW276.

  • Age:

    18 Years and Older

  • Mutation(s):

    Two Copies F508del

  • FEV1% Predicted:

    40 to 100%

  • Number of Visits:

    15

  • Length of Participation:

    3 months

• Anti-InflammatoryEnrolling

  Phase 2 study of lenabasum in people with CF ages 12 and older , protocol number Corbus JBT101-CF-002

  This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the potential anti-inflammatory drug lenabasum and will use a placebo control.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 100%

  • Number of Visits:

    10

  • Length of Participation:

    32 weeks

• Anti-InfectiveEnrolling

  Phase 2 study of inhaled nitric oxide in people with CF , protocol number Novoteris NO-CF-02E

  This study is taking place at multiple care centers across the U.S. It will look at the effectiveness of the inhaled drug nitric oxide in adults with cystic fibrosis who are taking an inhaled antibiotic.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    35 to 85%

  • Number of Visits:

    10

  • Length of Participation:

    43 days

• Nutritional-GIEnrolling

  Phase 2 study of oral glutathione in children with cystic fibrosis , protocol number GROW-IP-16

  This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the oral drug glutathione in children with cystic fibrosis.

  • Age:

    24 Months to 10 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    4

  • Length of Participation:

    6 months

• ObservationalEnrolling

  Sweat chloride observational study , protocol number CHEC-OB-17

  This study is taking place at multiple care centers across the U.S. It will look at sweat chloride concentration in people who are currently taking CFTR modulators.

  • Age:

    4 Months and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    1

  • Length of Participation:

    1 days

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.